Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Clinical Trial

Official title: A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Status Active, not recruiting

Clinical Trial Summary

This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma
• Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

• NCT number: NCT04848753
• Study type: Interventional
• Source: Shanghai Junshi Bioscience Co., Ltd.
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 23, 2021
• Completion date: May 12, 2027